Fox Run Management L.L.C. Acquires Shares of 21,738 Harmony Biosciences Holdings, Inc. $HRMY

Fox Run Management L.L.C. acquired a new stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) during the fourth quarter, Holdings Channel reports. The firm acquired 21,738 shares of the company’s stock, valued at approximately $813,000.

Other institutional investors also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC boosted its holdings in Harmony Biosciences by 589.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 752 shares of the company’s stock valued at $28,000 after purchasing an additional 643 shares in the last quarter. Leonteq Securities AG acquired a new stake in Harmony Biosciences during the fourth quarter valued at approximately $30,000. Allworth Financial LP boosted its holdings in Harmony Biosciences by 286.7% during the fourth quarter. Allworth Financial LP now owns 812 shares of the company’s stock valued at $30,000 after purchasing an additional 602 shares in the last quarter. Clearstead Advisors LLC boosted its holdings in shares of Harmony Biosciences by 145.9% in the 4th quarter. Clearstead Advisors LLC now owns 1,178 shares of the company’s stock worth $44,000 after acquiring an additional 699 shares in the last quarter. Finally, National Bank of Canada FI acquired a new position in shares of Harmony Biosciences in the 3rd quarter worth approximately $40,000. 86.23% of the stock is owned by institutional investors and hedge funds.

Harmony Biosciences Stock Up 4.0%

NASDAQ:HRMY opened at $35.48 on Thursday. The stock’s fifty day moving average price is $30.58 and its two-hundred day moving average price is $33.12. Harmony Biosciences Holdings, Inc. has a 52-week low of $25.52 and a 52-week high of $40.87. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.56 and a current ratio of 3.58. The company has a market cap of $2.05 billion, a price-to-earnings ratio of 14.31, a P/E/G ratio of 0.24 and a beta of 0.96.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.55 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.21). Harmony Biosciences had a return on equity of 17.19% and a net margin of 16.20%.The firm had revenue of $215.39 million for the quarter, compared to analyst estimates of $220.84 million. During the same period in the prior year, the company posted $0.78 EPS. The firm’s quarterly revenue was up 16.6% compared to the same quarter last year. On average, analysts anticipate that Harmony Biosciences Holdings, Inc. will post 3.2 EPS for the current year.

Wall Street Analysts Forecast Growth

HRMY has been the topic of several recent analyst reports. Needham & Company LLC reduced their target price on Harmony Biosciences from $46.00 to $44.00 and set a “buy” rating on the stock in a report on Wednesday, February 25th. Weiss Ratings downgraded Harmony Biosciences from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, April 29th. Deutsche Bank Aktiengesellschaft downgraded Harmony Biosciences from a “buy” rating to a “hold” rating and set a $31.00 target price on the stock. in a report on Monday, February 23rd. Mizuho set a $50.00 target price on Harmony Biosciences in a report on Thursday, February 19th. Finally, Zacks Research raised Harmony Biosciences from a “strong sell” rating to a “hold” rating in a report on Friday, May 1st. Four equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $40.89.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.